Asia-Pacific Cancer Biomarker Testing Market Research Report by Type (Product and Services), by Testing Type (Single Gene Testing and Multiple Gene Testing), by Region (China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan) Forecast to 2032
Market Overview
Asia-Pacific Cancer the biomarker testing market is expected to grow at a significant CAGR of 12.58% during the review period.
Cancer biomarker testing uses biological markers such as chemicals or genes found in blood, tissues, or other physiological fluids to identify the presence, progression, or risk of cancer. These biomarkers can provide vital insights into a tumor's genetic, genomic, and cellular characteristics, allowing for early detection, diagnosis, prognosis, and treatment selection. Biomarker testing helps clinicians discover the specific characteristics of a patient's cancer, allowing for more individualised treatment plans. Biomarkers in cancer might be genetic (e.g., DNA mutations), proteomic (protein-related), or epigenetic. NGS, PCR, and immunohistochemistry are some of the testing methods used. Cancer biomarker testing is particularly beneficial for targeted therapies and immunotherapies because it identifies patients who are most likely to benefit from specific treatments based on the genetic makeup of their tumours. Biomarker testing not only guides medicine but also serves to monitor disease progression, detect recurrences, and assess therapy response. As cancer research advances, biomarker testing becomes a more significant tool for improving cancer care outcomes and fostering precision medicine.
Market Segmentation
The Asia-Pacific cancer biomarker testing market is divided into two segments: products and services. The product category dominated the market in 2023, while the services sector is expected to grow the fastest over the forecast period (2024-2032).
The Asia-Pacific cancer biomarker testing market is divided into two segments based on testing type: single gene and multiple gene. The multiple gene testing category dominated the market in 2023 and is expected to expand the quickest over the forecast period (2024-2032).
The global Asia-Pacific Cancer biomarker testing market is divided into the following countries: China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan. The China sector had the greatest market share in 2023, while India is the fastest-growing segment throughout the projection period (2024-2032).
Major Players
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences, Qiagen N.V., and Oxford Nanopore Technologies Plc. are the market's leading companies.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 32
TABLE 2 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 53
TABLE 3 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR PRODUCTS, BY TYPE, 2019–2032 (USD THOUSAND) 53
TABLE 4 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SERVICES, BY VOLUME (NUMBER OF TESTS), 2019–2032 53
TABLE 5 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR PRODUCTS, BY COUNTRY, 2019–2032 (USD THOUSAND) 54
TABLE 6 GLOBAL MARINE COLLAGEN MARKET, FOR SERVICES, BY COUNTRY, 2019–2032 (USD THOUSAND) 55
TABLE 7 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 58
TABLE 8 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 58
TABLE 9 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 58
TABLE 10 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, BY TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 59
TABLE 11 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 59
TABLE 12 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 60
TABLE 13 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, BY COUNTRY, 2019–2032 (USD THOUSAND) 61
TABLE 14 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY COUNTRY, 2019–2032 (USD THOUSAND) 62
TABLE 15 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY, 2019–2032 (USD THOUSAND) 65
TABLE 16 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY, VOLUME (NUMBER OF TESTS), 2019–2032 66
TABLE 17 INDIA CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 67
TABLE 18 INDIA CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019–2032 (USD THOUSAND) 67
TABLE 19 INDIA CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 67
TABLE 20 INDIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 68
TABLE 21 INDIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 68
TABLE 22 INDIA CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019–2032 (USD THOUSAND) 68
TABLE 23 INDIA CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 69
TABLE 24 INDIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019–2032 (USD THOUSAND) 70
TABLE 25 INDIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 70
TABLE 26 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 71
TABLE 27 AUSTRALIA CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019–2032 (USD THOUSAND) 71
TABLE 28 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 71
TABLE 29 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 72
TABLE 30 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 72
TABLE 31 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019–2032 (USD THOUSAND) 72
TABLE 32 AUSTRALIA CANCER BIOMARKER TESTING MARKET, FOR SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 73
TABLE 33 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019–2032 (USD THOUSAND) 73
TABLE 34 AUSTRALIA CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 74
TABLE 35 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 75
TABLE 36 HONG KONG CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019–2032 (USD THOUSAND) 75
TABLE 37 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 75
TABLE 38 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 76
TABLE 39 HONG KONG CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 76
TABLE 40 HONG KONG CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019–2032 (USD THOUSAND) 76
TABLE 41 HONG KONG CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 77
TABLE 42 HONG KONG CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019–2032 (USD THOUSAND) 77
TABLE 43 HONG KONG CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 78
TABLE 44 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 79
TABLE 45 TAIWAN CANCER BIOMARKER TESTING MARKET, FOR PRODUCT, BY TYPE, 2019–2032 (USD THOUSAND) 79
TABLE 46 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 79
TABLE 47 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 80
TABLE 48 TAIWAN CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, VOLUME (NUMBER OF TESTS), 2019–2032 80
TABLE 49 TAIWAN CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, 2019–2032 (USD THOUSAND) 80
TABLE 50 TAIWAN CANCER BIOMARKER TESTING MARKET, BY SINGLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 81
TABLE 51 TAIWAN CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, 2019–2032 (USD THOUSAND) 81
TABLE 52 TAIWAN CANCER BIOMARKER TESTING MARKET, BY MULTIPLE GENE TESTING, VOLUME (NUMBER OF TESTS), 2019–2032 82
TABLE 53 CHINA: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 83
TABLE 54 CHINA: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019–2032 (USD THOUSAND) 83
TABLE 55 CHINA: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019–2032 (NO. OF TESTS) 83
TABLE 56 CHINA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 84
TABLE 57 CHINA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (NO. OF TESTS) 84
TABLE 58 CHINA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 84
TABLE 59 CHINA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (NO. OF TESTS) 85
TABLE 60 CHINA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 85
TABLE 61 CHINA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 86
TABLE 62 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 87
TABLE 63 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019–2032 (USD THOUSAND) 87
TABLE 64 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019–2032 (NO. OF TESTS) 88
TABLE 65 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 88
TABLE 66 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (NO. OF TESTS) 88
TABLE 67 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 89
TABLE 68 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (NO. OF TESTS) 89
TABLE 69 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 90
TABLE 70 SOUTH KOREA: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 90
TABLE 71 THAILAND: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 91
TABLE 72 THAILAND: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019–2032 (USD THOUSAND) 91
TABLE 73 THAILAND: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019–2032 (NO. OF TESTS) 92
TABLE 74 THAILAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 92
TABLE 75 THAILAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (NO. OF TESTS) 92
TABLE 76 THAILAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 93
TABLE 77 THAILAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (NO. OF TESTS) 93
TABLE 78 THAILAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 94
TABLE 79 THAILAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 94
TABLE 80 JAPAN: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 95
TABLE 81 JAPAN: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019–2032 (USD THOUSAND) 95
TABLE 82 JAPAN: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019–2032 (NO. OF TESTS) 96
TABLE 83 JAPAN: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 96
TABLE 84 JAPAN: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (NO. OF TESTS) 96
TABLE 85 JAPAN: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 97
TABLE 86 JAPAN: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (NO. OF TESTS) 97
TABLE 87 JAPAN: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 98
TABLE 88 JAPAN: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 98
TABLE 89 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 99
TABLE 90 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019–2032 (USD THOUSAND) 99
TABLE 91 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019–2032 (NO. OF TESTS) 100
TABLE 92 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 100
TABLE 93 SINGAPORE: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (NO. OF TESTS) 100
TABLE 94 SINGAPORE: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 101
TABLE 95 SINGAPORE: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (NO. OF TESTS) 101
TABLE 96 SINGAPORE: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 102
TABLE 97 SINGAPORE: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 102
TABLE 98 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY TYPE, 2019–2032 (USD THOUSAND) 103
TABLE 99 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY PRODUCT, 2019–2032 (USD THOUSAND) 103
TABLE 100 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY SERVICES, 2019–2032 (NO. OF TESTS) 104
TABLE 101 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (USD THOUSAND) 104
TABLE 102 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2019–2032 (NO. OF TESTS) 104
TABLE 103 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 105
TABLE 104 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, SINGLE GENE TESTING, BY TYPE, 2019–2032 (NO. OF TESTS) 105
TABLE 105 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 106
TABLE 106 NEW ZEALAND: CANCER BIOMARKER TESTING MARKET, FOR MULTIPLE GENE TESTING, BY TYPE, 2019–2032 (USD THOUSAND) 106
TABLE 107 PRODUCT LAUNCH 111
TABLE 108 PRODUCT APPROVAL 111
TABLE 109 COLLABORATION 112
TABLE 110 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 115
TABLE 111 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 115
TABLE 112 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 118
TABLE 113 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 119
TABLE 114 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 122
TABLE 115 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 123
TABLE 116 ILLUMINA, INC.: PRODUCTS OFFERED 126
TABLE 117 ILLUMINA, INC.: KEY DEVELOPMENTS 127
TABLE 118 PACIFIC BIOSCIENCES: PRODUCTS OFFERED 129
TABLE 119 PACIFIC BIOSCIENCES: PRODUCTS OFFERED 130
TABLE 120 GENEWIZ, INC.: SERVICE OFFERED 132
TABLE 121 QIAGEN N.V.: PRODUCT OFFERED 135
TABLE 122 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS OFFERED 139
TABLE 123 MGI TECH CO., LTD.: PRODUCT OFFERED 141
TABLE 124 BIOSERVE: SERVICE OFFERED 143
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET: STRUCTURE 19
FIGURE 2 ASIA PACIFIC CANCER BIOMARKER TESTING MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 36
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 38
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 39
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET 41
FIGURE 6 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSAND) 52
FIGURE 7 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TYPE, 2023 & 2032 (USD THOUSAND) 52
FIGURE 8 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET SHARE (%), BY TYPE, 2023 54
FIGURE 9 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, TESTING TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSAND) 57
FIGURE 10 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE, 2023 & 2032 (USD THOUSAND) 57
FIGURE 11 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET SHARE (%), BY TESTING TYPE, 2023 60
FIGURE 12 ASIA-PACIFIC MARKET ANALYSIS: CANCER BIOMARKER TESTING MARKET, 2019-2032 (USD THOUSAND) 64
FIGURE 13 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY, 2023 & 2032 (USD THOUSAND) 65
FIGURE 14 ASIA-PACIFIC CANCER BIOMARKER TESTING SHARE (%), BY COUNTRY, 2023 66
FIGURE 15 ASIA PACIFIC CANCER BIOMARKER TESTING MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 108
FIGURE 16 COMPETITOR DASHBOARD: ASIA PACIFIC CANCER BIOMARKER TESTING MARKET 109
FIGURE 17 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 114
FIGURE 18 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 116
FIGURE 19 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 118
FIGURE 20 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 120
FIGURE 21 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 122
FIGURE 22 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 123
FIGURE 23 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT 126
FIGURE 24 PACIFIC BIOSCIENCES: FINANCIAL OVERVIEW SNAPSHOT 129
FIGURE 25 GENEWIZ, INC.: SWOT ANALYSIS 133
FIGURE 26 QIAGEN N.V.: FINANCIAL OVERVIEW SNAPSHOT 135
FIGURE 27 QIAGEN N.V.: SWOT ANALYSIS 137
FIGURE 28 OXFORD NANOPORE TECHNOLOGIES PLC: FINANCIAL OVERVIEW SNAPSHOT 139
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們